Pharmaceutics

Chemotherapy is often a central component of treatment for advanced colorectal cancer. However, not every therapy is equally effective for every patient. Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* stem cell institute, and the biotech company Xilis in Utrecht, Netherlands, have now developed a new method for selecting the most effective drug before treatment begins.

New findings indicate that a shingles vaccination could not only reduce the risk of cognitive impairment and dementia, but also reduce disease progression among those living with dementia.

Alithea Biotechnology GmbH - 12/02/2026

Intelligent immunotherapy – safety ensured

Immunological cell fingerprints are Alithea Bio’s core expertise. The Freiburg-based company combines advanced molecular biology with cutting-edge IT and operates one of the world’s largest immunopeptidomics databases. Alithea Bio leverages this integrated platform to offer both contract research services and software-as-a-service solutions to develop safer and more precise personalised immunotherapies more quickly.

Rewriting the transcript to heal diseases - 29/01/2026

Therapy involving the umlauts of the genetic alphabet

tRNAs are essential components of the protein synthesis machinery that also act as molecular switches in gene regulation and consequently in disease processes such as cancer. The Heidelberg-based start-up Umlaut.bio is developing novel therapeutics that specifically target tRNAs to intervene at the molecular origin of disease.

Dossier - 20/11/2025

Prevention as the key to health

Many serious illnesses can be prevented or at least mitigated through healthy lifestyles and early diagnosis. However, effective prevention requires holistic approaches at all levels of healthcare and the reinforcement of individual health literacy.

Human immunodeficiency viruses (HIV) are insidious. They can evade the immune defence and antiviral drugs by becoming "latent". In this state, they are largely invisible and unassailable. As long as these dormant viruses persist, there is no cure for HIV/AIDS. However, researchers at Ulm University Hospital have discovered a new way to reactivate latent HI viruses.

About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, clinicians have treated all patients with these fusions the same way. However, new research led by scientists from the German Cancer Research Center (DKFZ) and Stanford University shows that not all fusion variants behave alike.

The groninger Group has acquired Reinraumtechnik Ulm GmbH (RTU). With this strategic move, the family-owned company headquartered in Crailsheim not only expands its technological portfolio but also strengthens its expertise in a field that is crucial to the pharmaceutical industry: cleanroom and isolator technology.

Researchers at Heidelberg Uni Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human genome. A research team identified RNA:DNA hybrids as molecular signposts for the virus. These findings reveal a vulnerability in the life cycle of HIV and provide therapeutic approaches for specifically controlling HIV reservoirs in the body. This has been one of the obstacles to curative HIV therapies.

Until now, the early phase of drug discovery for the development of new therapeutics has been cost- and time-intensive. Researchers at KIT have developed a platform on which extremely miniaturized nanodroplets with a volume of 200 nanoliters per droplet and containing 300 cells per test can be arranged. This platform enables the researchers to synthesize and test thousands of therapeutic agents on the same chip, saving time and resources.

Diabetics have a higher risk of colorectal cancer and often a poorer prognosis after developing the disease. The biological mechanisms behind this association were largely unknown. A research team at the German Cancer Research Center (DKFZ) has now discovered that tumors with a low number of immune cells appear to be particularly susceptible to the harmful effects of diabetes.

Study led by the University of Tübingen: many non-antibiotics weaken the natural protective function of the intestine – with consequences for the colonization with pathogenic bacteria